Allergic rhinitis—commonly known as hay fever—affects hundreds of millions worldwide and is driven by allergens such as pollen, dust mites, and pet dander. With changing lifestyles and worsening air quality in urban regions, patient populations continue to rise. Pharmaceutical companies are focusing on improving treatment efficacy, convenience, and safety, which is fueling market growth. The global Allergic Rhinitis Drugs Market is poised for steady expansion through the next decade, supported by rising allergy prevalence, growing environmental pollution, and increasing awareness of effective treatments. According to market estimates, the market is projected to reach US$ 20.5 billion by 2034, growing from US$ 16.67 billion in 2025, at a CAGR of 2.62% from 2026 to 2034. The growth trajectory reflects the chronic nature of allergic rhinitis and the continuous demand for long-term symptom management therapies. Read More - https://www.theinsightpartners.com/reports/allergic-rhinitis-drugs-market